Ilker Ilhanlı
Giresun University School of Medicine,Turkey
Title: Papillary thyroid carcinoma during etanercept therapy in a patient with psoriatic arthritis
Biography
Biography: Ilker Ilhanlı
Abstract
In recent years usage of the Tumor necrosis alpha blockers (Anti-TNFα) in rheumatologic diseases has been increased and their efficacy has been proved. Etanercept is a fusion protein resembling TNF receptors type-II, which acts by blocking circulating TNF and lymphotoxin-a. It is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis and severely active polyarticular juvenile idiopathic arthritis in children aged 2 years and older. While the importance of these drugs is folding up, some questions are appearing in the minds, like whether they lead or facilitate the malign process. Thyroid cancer is the most common malignant tumor of the endocrine system. The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer. The most frequent type of thyroid malignancy is papillary carcinoma. Here we reported a 52 years old female patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis.